PLXProtalix BioTherapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Protalix BioTherapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLXThis | $219M#4 | 11.8x#2 | 3.1x#4 | 4.1x#1 | -1.2%#1 | -325.2%#4 | -10.4%#1 | -9.2%#2 | -12.3%#1 | 3#1 | 47.6%#2 | — |
| SABS | $316M#1 | 14.5x#3 | 1.5x#1 | — | -100.0%#3 | 138.9%#1 | — | 6.2%#1 | — | — | — | — |
| FATE | $304M#2 | — | 2.0x#2 | 45.8x#2 | -51.2%#2 | 26.8%#2 | -2222.4%#2 | -88.8%#4 | -102.3%#2 | — | 166.4%#1 | — |
| PALI | $301M#3 | 2.7x#1 | 2.5x#3 | — | — | -16.2%#3 | — | -13.8%#3 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice